This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

9 Meters Biopharma Performance dei guadagni passati

Il passato criteri di controllo 0/6

9 Meters Biopharma's earnings have been declining at an average annual rate of -15.8%, while the Pharmaceuticals industry saw earnings growing at 7.6% annually.

Informazioni chiave

-15.8%

Tasso di crescita degli utili

47.6%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore	7.3%
Tasso di crescita dei ricavi	n/a
Rendimento del capitale proprio	n/a
Margine netto	n/a
Ultimo aggiornamento sui guadagni	31 Mar 2023

Aggiornamenti sulle prestazioni recenti

Nessun aggiornamento

Recent updates

Ripartizione dei ricavi e delle spese

Come 9 Meters Biopharma guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

DB:2Q3A Ricavi, spese e utili (USD Millions )
Data	Guadagni	Spese G+A	Spese di R&S
31 Mar 23	-46	11	32
31 Dec 22	-44	11	31
30 Sep 22	-41	11	29
30 Jun 22	-46	11	29
31 Mar 22	-43	10	27
31 Dec 21	-37	9	22
30 Sep 21	-32	8	18
30 Jun 21	-27	8	17
31 Mar 21	-63	10	12
31 Dec 20	-61	10	11
30 Sep 20	-65	10	13
30 Jun 20	-66	11	12
31 Mar 20	-26	9	15
31 Dec 19	-27	10	14
30 Sep 19	-22	10	10
30 Jun 19	-14	9	4
31 Mar 19	-14	9	2
31 Dec 18	-24	11	8
30 Sep 18	-22	10	7
30 Jun 18	-24	10	9
31 Mar 18	-23	10	9
31 Dec 17	-12	7	4
30 Sep 17	-11	7	4

Guadagni di qualità: 2Q3A is currently unprofitable.

Margine di profitto in crescita: 2Q3A is currently unprofitable.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: 2Q3A is unprofitable, and losses have increased over the past 5 years at a rate of 15.8% per year.

Accelerare la crescita: Unable to compare 2Q3A's earnings growth over the past year to its 5-year average as it is currently unprofitable

Guadagni vs Settore: 2Q3A is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (11%).

Rendimento del capitale proprio

ROE elevato: 2Q3A's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

This company listing is no longer active

9 Meters Biopharma Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Recent updates

9 Meters Biopharma Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Rule

9 Meters Biopharma, Inc. Appoints Bethany Sensenig as Interim CEO

9 Meters Biopharma, Inc. Announces the Resignation of John Temperato as President

9 Meters Biopharma, Inc. Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome

High number of new and inexperienced directors

9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA for Vurolenatide in Short Bowel Syndrome

9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome

9 Meters Biopharma, Inc. announced that it expects to receive $70 million in funding

9 Meters Biopharma, Inc., Annual General Meeting, Jun 22, 2022

High number of new and inexperienced directors

President recently bought €50k worth of stock

9 Meters Biopharma Provides Clinical Update on Late-Stage Pipeline Products Vurolenatide for Short Bowel Syndrome and Larazotide for Celiac Disease

Independent Chairman recently bought €84k worth of stock

9 Meters Biopharma, Inc. Announces Initiation of Phase 2 Vibrant Study of Vurolenatide for Short Bowel Syndrome

9 Meters Biopharma, Inc. Announces Publication in Journal of Clinical Investigation Describing Successful Use of Larazotide for Treating Multisystem Inflammatory Syndrome in Children Resulting from Covid-19 Infection

9 Meters Biopharma, Inc. Receives USAN Approval to Use the Designated Nonproprietary Name Vurolenatide for Its Long-Acting GLP-1 Agonist for Short Bowel Syndrome

Forecast to breakeven in 2024

9 Meters Biopharma Hosting Key Opinion Leader Webinar on Short Bowel Syndrome and NM-002 Program Update

9 Meters Biopharma Inc Appoints Michael Rice as Board of Director

New 90-day high: €1.86

9 Meters Biopharma, Inc. Announces the Resignation of Nissim Darvish as Director

Independent Director has left the company

New 90-day high: €1.22

New 90-day high: €1.19

9 Meters Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $30.000001 million.

New 90-day high: €0.85

9 Meters Biopharma Announces Positive Preclinical Data for NM-102, a Gut Microbiome Modulator in an Immune Checkpoint Inhibitor Failure Model

Independent Chairman recently bought €81k worth of stock

New 90-day high - €0.74

Innovate Biopharmaceuticals, Inc. (NasdaqCM:INNT) completed the acquisition of RDD Pharma, Ltd. from OrbiMed Israel Partners managed by OrbiMed Advisors, L.L.C. and others.

9 Meters Biopharma, Inc.(NasdaqCM:NMTR) dropped from Russell Microcap Index

Ripartizione dei ricavi e delle spese

Storia dei guadagni e delle entrate

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Rendimento del capitale proprio

Rendimento delle attività

Rendimento del capitale investito

Scoprire le aziende con forti performance passate